Print this page for your doctor
CLINICAL TRIAL SUMMARY
MDACC Study No:
(clinicaltrials.gov NCT No:
A Phase 2, Open-Label, Prospective Study Of PRM-151 In Subjects
With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF
(post-PV MF), Or Post-Essential Thrombocythemia MF (post-ET
The goal of this clinical research study is to learn if PRM-151 can help to
control MF. Two (2) different dosing schedules will be compared. The safety
of this drug will also be studied.
PRM-151 is designed to be active at places in the body where there is tissue
damage, which may help to control tissue scarring.
Some participants will also receive ruxolitinib. Ruxolitinib is designed to
block some of the proteins in the blood that may cause MF symptoms.
Phase of Study:
Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Study Contact Information
For Clinical Trial Enrollment:
For General Questions about Clinical Trials:
Study Objectives / Outcomes
Study Status Information
Resources and Links
Return to List